Premium
International Society of Blood Transfusion Working Party on Red Cell Immunogenetics and Blood Group Terminology: Report of the Dubai, Copenhagen and Toronto meetings
Author(s) -
Storry Jill R.,
Clausen Frederik Banch,
Castilho Lilian,
Chen Qing,
Daniels Geoff,
Denomme Greg,
Flegel Willy A,
Gassner Christoph,
Haas Masja,
Hyland Catherine,
Yanli Ji,
Keller Margaret,
LomasFrancis Christine,
Nogues Nuria,
Olsson Martin L,
Peyrard Thierry,
Schoot Ellen,
Tani Yoshihiko,
Thornton Nicole,
Wagner Franz,
Weinstock Christoph,
Wendel Silvano,
Westhoff Connie,
Yahalom Vered
Publication year - 2019
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/vox.12717
Subject(s) - antigen , transfusion medicine , medicine , blood transfusion , immunogenetics , serology , immunology , antibody
Background and objectives The International Society of Blood Transfusion ( ISBT ) Working Party for Red Cell Immunogenetics and Blood Group Terminology meets in association with the ISBT congress and has met three times since the last report: at the international meetings held in Dubai, United Arab Emirates, September 2016 and Toronto, Canada, June 2018; and at a regional congress in Copenhagen, Denmark, June 2017 for an interim session. Methods As in previous meetings, matters pertaining to blood group antigen nomenclature and classification were discussed. New blood group antigens were approved and named according to the serologic and molecular evidence presented. Results and conclusions Fifteen new blood group antigens were added to eight blood group systems. One antigen was made obsolete based on additional data. Consequently, the current total of blood group antigens recognized by the ISBT is 360, of which 322 are clustered within 36 blood groups systems. The remaining 38 antigens are currently unassigned to a known system. Clinically significant blood group antigens continue to be discovered, through serology/sequencing and/or recombinant or genomic technologies.